Corcept Therapeutics
Clinical trials sponsored by Corcept Therapeutics, explained in plain language.
A commercial-stage pharmaceutical company developing drugs for severe metabolic and psychiatric disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise against fatty liver disease in Mid-Stage trial Results expected Sep 2026 (estimated)
- New drug duo aims to fight Hard-to-Treat cancers Results expected Sep 2026 (estimated)
- New hope for ALS: experimental drug aims to slow muscle decline Results expected Oct 2026 (estimated)
- New drug miricorilant tested for fatty liver disease safety Results expected Oct 2026 (estimated)
- New drug shows promise for Long-Term control of cushing syndrome Results expected Dec 2026 (estimated) May already have reported ↗
-
New drug shows promise for Long-Term control of cushing syndrome
Disease control OngoingThis study looks at the long-term safety of relacorilant, a drug for people with Cushing syndrome. It includes 125 adults who previously completed a relacorilant study and may benefit from continued treatment. Researchers will track side effects over time to see if the drug is sa…
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to shrink fatty liver in early trial
Disease control OngoingThis early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have cer…
Phase 1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants are randomly assigned to receive either the drug or a placebo, and researchers measure changes in liver fat using MRI scan…
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC